Feedback
Settings

Settings

Goto Application

6,155 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(USVMJSALORZVDV-SDBHATRESA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 616
1.WO/2026/006708ANTI-CD25 ANTIGEN-BINDING PROTEINS AND USES THEREOF
WO - 02.01.2026
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2025/035662 Applicant ODYSSEY THERAPEUTICS, INC. Inventor FRANCHI, Luigi
The present application provides antigen-binding proteins (e.g., antibodies such as single-domain antibodies) that specifically bind cluster of differentiation 25 (CD25). The application also provides fusion proteins and conjugates comprising the antigen-binding proteins, polynucleotides and recombinant vectors encoding the antigen-binding proteins, as well as host cells and methods for preparing the antigen-binding proteins. The application further provides pharmaceutical compositions comprising the antigen-binding proteins.
2.WO/2026/006739BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS FOR THE TREATMENT OF CERTAIN DISEASES
WO - 02.01.2026
Int.Class A61K 31/517
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
 Appl.No PCT/US2025/035705 Applicant RIBOSCIENCE LLC Inventor HAWLEY, Ronald
The present disclosure provides certain bicyclic heteroaryl phosphonate and boronate compounds that inhibit ectonucleotide pyrophosphatase/ phosphodiesterase 1 (ENPP1) enzymatic activity for the treatment of certain diseases mediated by upregulation of ENPP1 such as cancers, inflammatory diseases, and viral infections. Also provided are pharmaceutical compositions containing such compounds.
3.WO/2026/006809MULTISPECIFIC MOLECULES BINDING TNFR2 AND CD25 AND USES THEREOF
WO - 02.01.2026
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2025/035805 Applicant ODYSSEY THERAPEUTICS, INC. Inventor FRANCHI, Luigi
The present application provides multispecific antigen-binding proteins (e.g., antibodies) that specifically bind tumor necrosis factor receptor 2 (TNFF52) and cluster of differentiation 25 (CD25). The application also provides conjugates comprising the multispecific antigen-binding proteins, polynucleotides and recombinant vectors encoding the multispecific antigen-binding proteins, as well as host cells and methods for preparing the multispecific antigen-binding proteins. The application further provides pharmaceutical compositions comprising the multispecific antigen-binding proteins and methods for treating a disease or disorder using the multispecific antigen-binding proteins.
4.WO/2026/006413IL-12 PRODRUGS, METHODS OF USE AND PHARMACEUTICAL COMPOSITIONS
WO - 02.01.2026
Int.Class A61K 38/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins
 Appl.No PCT/US2025/035200 Applicant WEREWOLF THERAPEUTICS, INC. Inventor ISAACS, Randi
This disclosure relates to methods and compositions for treating cancer including advanced solid tumor, a metastatic solid tumor or lymphoma using an inducible IL-12 prodrug.
5.WO/2025/259572INTEGRIN BETA 6 (ITGB6) TARGETING TRISPECIFIC PROTEIN FOR TREATMENT OF CANCER
WO - 18.12.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2025/032813 Applicant HARPOON THERAPEUTICS, INC. Inventor AUSTIN, Richard J.
Provided herein are ITGB6 binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such ITGB6 binding proteins. Also disclosed are methods of using the disclosed ITGB6 binding proteins in the prevention, and/or treatment diseases, conditions and disorders associated with ITGB6.
6.WO/2025/259802COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER
WO - 18.12.2025
Int.Class A61K 47/69
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
 Appl.No PCT/US2025/033231 Applicant UNIVERSITY OF MASSACHUSETTS Inventor ATUKORALE, Prabhani
The present disclosure relates to compositions comprising a population of immunomodulatory lipid nanoparticles, as well as methods of using thereof to treat and/or prevent cancer (e.g., via local administration to the lymph nodes) and methods of using thereof to treat and/or prevent cancer metastasis in a subject.
7.20250376689OLIGONUCLEOTIDES HAVING 6-THIO-2'-DEOXYGUANOSINE RESIDUES AND USES THEREOF
US - 11.12.2025
Int.Class C12N 15/117
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
 Appl.No 18686588 Applicant City of Hope Inventor Marcin Tomasz Kortylewski

The disclosure provides, inter alia, oligonucleotides comprising 6-thio-2′-deoxy-guanosine residues. The oligonucleotides comprising said residues are used in pharmaceutical compositions and methods for treating cancer. The invention also includes CpG oligodeoxynucleotides in combination with the 6-thio-2-deoxy-guanosine residues in said pharmaceutical compositions and methods for treating cancer. Oligonucleotides of the invention may also include additional therapeutic moieties or exonuclease resistant moieties. The compositions and methods of the invention may employ additional pharmaceutical entities for the treatment of cancer.

8.WO/2025/250823DNA-ENCODED MULTIVALENT ANTIBODIES TARGETING CARBONIC ANHYDRASE 9 AND METHODS OF USE IN CANCER THERAPEUTICS
WO - 04.12.2025
Int.Class C07K 16/40
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
40against enzymes
 Appl.No PCT/US2025/031479 Applicant THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY Inventor O'CONNELL, Ryan
Disclosed herein are methods of treating or preventing renal cell carcinoma comprising administering compositions comprising a recombinant nucleic acid sequence encoding a therapeutic antibody targeting CA9, a fragment thereof, a variant thereof, or a combination thereof.
9.20250368677CD73 INHIBITORS
US - 04.12.2025
Int.Class C07H 19/23
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14-C07H19/22222
 Appl.No 19234635 Applicant ORIC Pharmaceuticals, Inc. Inventor Xiaohui DU

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

10.WO/2025/250826PERSISTENT T-CELL ENGAGERS TARGETING FSHR AND METHODS OF USE IN CANCER THERAPEUTICS
WO - 04.12.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2025/031483 Applicant THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY Inventor BORDOLOI, Devivasha
Disclosed herein are compositions comprising persistent bispecific anti-FSHR T cell engagers and a persistent multivalent anti-FSHR T cell engagers, fragments thereof, variants thereof, combinations thereof, and recombinant nucleic acid sequences encoding the same, fragments thereof, variants thereof, combinations thereof, and methods of use thereof.
# -